9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC

G. Finocchiaro, A. Santoro, F. Grossi, P. Bidoli, A. Favaretto, L. Clementi, D. Massey, R. Lorence, F. Cappuzzo
  • European Journal of Cancer, September 2011, Elsevier
  • DOI: 10.1016/s0959-8049(11)72319-x

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication


The following have contributed to this page: Dr Federico Cappuzzo